Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. - Wikidata - wikimedia - TriplyDB

Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments.

Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments.

http://www.wikidata.org/entity/Q34622392

about

Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls Rapid antidepressant effects: moving right along A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression Bipolar disorder comorbid with alcoholism: a 1H magnetic resonance spectroscopy study Neurochemistry of the nucleus accumbens and its relevance to depression and antidepressant action in rodents Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review Functional regulation of GABAA receptors in nervous system pathologies Fgfr1 inactivation in the mouse telencephalon results in impaired maturation of interneurons expressing parvalbumin GABAA receptor-acting neurosteroids: a role in the development and regulation of the stress response Subanesthetic dose of ketamine decreases prefrontal theta cordance in healthy volunteers: implications for antidepressant effect The GABAβ receptor as a target for antidepressant drug action Biochemical, histopathological and morphological profiling of a rat model of early immune stimulation: relation to psychopathology Antidepressant and anxiolytic-like effects in mice lacking the group III metabotropic glutamate receptor mGluR7 Advances in the treatment of anxiety: targeting glutamate.A pilot in vivo proton magnetic resonance spectroscopy study of amino acid neurotransmitter response to ketamine treatment of major depressive disorder.Global brain gene expression analysis links glutamatergic and GABAergic alterations to suicide and major depression.Associations between prefrontal γ-aminobutyric acid concentration and the tryptophan hydroxylase isoform 2 gene, a panic disorder risk allele in women.Expression, purification and structural analysis of functional GABA transporter 1 using the baculovirus expression system.Antidepressants are a rational complementary therapy for the treatment of Alzheimer's disease.Relation between amygdala structure and function in adolescents with bipolar disorder Glutamine and glutamate levels in children and adolescents with bipolar disorder: a 4.0-T proton magnetic resonance spectroscopy study of the anterior cingulate cortex.A Ventral Prefrontal-Amygdala Neural System in Bipolar Disorder: A View from Neuroimaging Research Functional connectivity between ventral prefrontal cortex and amygdala at low frequency in the resting state in bipolar disorder Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression.Association of the GABRD gene and childhood-onset mood disorders Modulation of induced frontocentral theta (Fm-θ) event-related (de-)synchronisation dynamics following mindfulness-based cognitive therapy in Major Depressive Disorder Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders Genetic and pharmacological evidence of a role for GABA(B) receptors in the modulation of anxiety- and antidepressant-like behavior.The gamma amino butyric acid (GABA) receptor alpha-3 subunit gene polymorphism in unipolar depressive disorder: a genetic association study.Understanding the pharmacogenetics of selective serotonin reuptake inhibitors.Stuck in a rut: rethinking depression and its treatment.The antidepressant tianeptine persistently modulates glutamate receptor currents of the hippocampal CA3 commissural associational synapse in chronically stressed rats.Neurocircuitry of mood disorders.Stress impairs GABAergic network function in the hippocampus by activating nongenomic glucocorticoid receptors and affecting the integrity of the parvalbumin-expressing neuronal network.Diabetes as a chronic metabolic stressor: causes, consequences and clinical complications.Mitochondria, oligodendrocytes and inflammation in bipolar disorder: evidence from transcriptome studies points to intriguing parallels with multiple sclerosis Relationship between genetic variation in the glutaminase gene GLS1 and brain glutamine/glutamate ratio measured in vivo GABAergic contributions to alcohol responsivity during adolescence: insights from preclinical and clinical studies Association of rare variation in the glutamate receptor gene SLC1A2 with susceptibility to bipolar disorder and schizophrenia.Strain-dependent variations in stress coping behavior are mediated by a 5-HT/GABA interaction within the prefrontal corticolimbic system.

P2860

Q24550675-F2909963-5249-4D1F-AB62-DE546357AC93 Q24614410-CCCBAB1E-0498-47E0-BA3D-A69CF9B11F04 Q24630153-AC6C7ABE-E5BA-4616-90CB-B0E758D232E8 Q24630222-658AE2A9-B84D-415C-AC49-F6A7781343C6 Q24656267-34BA56BE-539F-48D4-9F14-6945DB2A3F1A Q26822244-62DAD309-C03E-427E-9450-407C7EE11A29 Q27013597-0806BCA5-6937-4782-AB7C-231E552F57C0 Q27316919-5435BB0B-7A2E-44B3-9C4E-32C53486BDF2 Q28241963-BD608B88-963C-43CF-B552-489C1F6F07B4 Q28267032-7E91AFE9-572E-4C86-A5F5-2F4EF1575024 Q28476654-D1C6F40C-95AE-49A6-9EF9-20FA943575EF Q28543041-363A0E29-2AC3-44AD-92AE-E1003A7E5951 Q28585707-BB793A18-2C94-4F5E-A7E0-8599F0C1A5C8 Q30457479-B5F197F8-944B-475A-BD6E-F099508BCC0E Q30987882-95025C86-D0F1-45B9-A11D-EEECE43BA82C Q33492323-100282B0-84F1-4D2E-85D9-805FDB44D3DA Q33630777-3E4DFEBC-879D-4D2B-ABA3-CB945587C7B4 Q33692210-EF952543-AF73-4CC1-BF32-161DD452FF9C Q33751924-280B3CFE-BC4A-4DC4-AA2C-AEA2583A3902 Q33839081-DEAD2A7E-8703-4685-B732-EFB89A9DB64F Q33874713-BD0461E7-973A-4779-9461-66C54A48F20B Q34025032-FA8E73CD-26E9-44D6-99EA-46BC317A81D7 Q34039941-723FC770-D212-41A7-B247-A17B7C72BB50 Q34084102-AD01AEAB-5C66-4D61-AEDF-7FFE9B04E442 Q34111492-CE4454B3-7996-4472-8AC9-9ADCC06F073C Q34135828-37767586-3CA2-4B9C-8EEC-E9B24DE09265 Q34204211-3FA5F2FC-04E4-4A24-92C8-F56E41E5EDF4 Q34308231-E120A4D9-CA09-4D73-9C0E-34CA0DBC440F Q34309220-00809882-69BF-4201-8E0A-6EFA754C825B Q34424865-4BEE5836-3DB8-4E9E-A76F-974F676758BA Q34459160-F412C939-EA0C-423D-82EE-12A2ECA145AA Q34528009-75F87DD9-6562-4B03-9604-DBB031D26E7B Q34660904-5FD35335-931F-4648-AFB7-3A1CD3454C1A Q34661056-02914ADD-FB23-4F5D-A86D-76EA9E347250 Q35032598-7965EA41-D6FD-4873-9377-6BF29811FE26 Q35053349-6EF55E1A-471B-4EB0-AC47-444561836040 Q35074537-2FEAC066-EE92-412A-AC6E-44C8A322438D Q35121218-FF6F7F5E-3C21-4233-9858-6A20C4C4CAF5 Q35154322-A7EE3D07-5C1A-48CA-A674-00D4111E3472 Q35179065-4C77868C-325B-46BB-9AA8-E3F3605BB49C

P2860

Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments.

http://www.wikidata.org/entity/Q34622392

description

2002 nî lūn-bûn

@nan

2002 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Glutamate and GABA systems as ...... d mood-stabilizing treatments.

@ast

Glutamate and GABA systems as ...... d mood-stabilizing treatments.

@en

Glutamate and GABA systems as ...... d mood-stabilizing treatments.

@nl

type

label

Glutamate and GABA systems as ...... d mood-stabilizing treatments.

@ast

Glutamate and GABA systems as ...... d mood-stabilizing treatments.

@en

Glutamate and GABA systems as ...... d mood-stabilizing treatments.

@nl

prefLabel

Glutamate and GABA systems as ...... d mood-stabilizing treatments.

@ast

Glutamate and GABA systems as ...... d mood-stabilizing treatments.

@en

Glutamate and GABA systems as ...... d mood-stabilizing treatments.

@nl

P1433

Q34622392-C9F11C59-0CEB-4145-9A7A-8B716411C024

P1476

Q34622392-BE60010D-A47D-4430-A259-2258D14D3A28

P2093

Q34622392-52224C47-2F54-4F91-B093-7D81DB4AC0F0

Q34622392-799A5B5B-4798-4A73-A692-7C2B21027ADD

Q34622392-87D08438-F7EF-43E3-B6AC-7E84131E40E3

Q34622392-B53AB838-41C9-494F-B46C-DA38652FBC04

Q34622392-B6C0F2DF-4CDB-4A89-A4DA-65F9DAD2B1D7

Q34622392-D04476CC-00A1-4A0A-A468-C51F7DB21D21

Q34622392-E55AE6B2-E28F-48D1-A276-C45839F53DB2

Q34622392-F554D717-C110-403F-871F-E8CDAFFF8725

P2860

Q34622392-00C63AB1-4256-471B-9BEF-369883886B42

Q34622392-00D0A08B-4D81-4B14-AEE0-CB26FCC889A2

Q34622392-0C81EF98-1D79-4F0B-878D-65823F741BAC

Q34622392-0CC1F1C3-3B74-4A45-A43C-D6FD1945E614

Q34622392-0E969229-34D2-41FE-85AF-A2C54625BF10

Q34622392-154EF33E-89B4-4DAA-ADD6-ACFA5DE78C9F

Q34622392-19821CF9-9EAD-458B-9F73-2224F50B72FB

Q34622392-25108C9B-3C52-4CB4-BE87-9376CBF43C4B

Q34622392-258FBE0D-0900-4327-8322-1742DF0CDFEE

Q34622392-2AA149F2-62D6-4A72-AEDE-847EFA1D537C

P2888

Q34622392-C3ADFF47-4145-4307-9B89-4640EC65A574

P304

Q34622392-EE0E73FA-BFB4-4A19-9B57-08976FA438BE

P31

Q34622392-49E4AA13-7A7A-490D-8BF4-58B3ED435C4D

P356

Q34622392-F2D0156C-6388-475A-A4C0-6860186EB662

P407

Q34622392-A89FB012-D872-4CC3-99E4-1010AEBCC25C

P478

Q34622392-6CDD5E1B-5DA5-4C1B-9546-55B157C9A4C8

P50

Q34622392-CFCCD2B7-3763-49B8-8D73-E06B3CD6715E

P577

Q34622392-8795AC92-8689-4D07-A664-B069266428BC

P5875

Q34622392-64A29432-5013-4D72-9685-72B112757F17

P6179

Q34622392-71D6990B-32D8-4F8E-929A-643A2C6E0BD5

P698

Q34622392-98481D31-5DE6-4D7D-8F34-32EE6C434E23

P356

P1433

Molecular Psychiatry

P1476

Glutamate and GABA systems as ...... d mood-stabilizing treatments.

@en

P2093

A Anand

http://www.w3.org/2001/XMLSchema#string

A Goddard

http://www.w3.org/2001/XMLSchema#string

C N Epperson

http://www.w3.org/2001/XMLSchema#string

D S Charney

http://www.w3.org/2001/XMLSchema#string

G F Mason

http://www.w3.org/2001/XMLSchema#string

G Marek

http://www.w3.org/2001/XMLSchema#string

G Sanacora

http://www.w3.org/2001/XMLSchema#string

J H Krystal

http://www.w3.org/2001/XMLSchema#string

P2860

Hippocampal atrophy in recurrent major depression

Serotonin model of schizophrenia: emerging role of glutamate mechanisms

Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats

Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET)

A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action

Amantadine-induced aggressiveness

Topiramate increases brain GABA, homocarnosine, and pyrrolidinone in patients with epilepsy

Antidepressant effects of ketamine in depressed patients

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

Prefrontal cortical-amygdalar metabolism in major depression.

P2888

P304

S71-80

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.MP.4001021

http://www.w3.org/2001/XMLSchema#string

P407

P478

7 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P50

Hilary P Blumberg

P577

2002-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11383078

http://www.w3.org/2001/XMLSchema#string

P6179

1018491212

http://www.w3.org/2001/XMLSchema#string

P698

11986998

http://www.w3.org/2001/XMLSchema#string